Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Allogeneic Stem Cell Transplant in Metastatic Kidney Cancer
NCT00056095Phase 2
Key facts
- Status
- Completed
- Start
- Nov 2002
- Primary completion
- Feb 2008
- Countries
- 1
- Sponsor
- Unicancer
- Modality
- Cell Therapies
- Conditions
- metastatic renal cell carcinoma (mRCC)
01
Overview
Phase 2, open-label trial of therapeutic allogeneic lymphocytes in metastatic renal cell carcinoma (mRCC), sponsored by Unicancer. Primary endpoints: Survival rate at 18 months, Objective rate of response and 2 more. Started Nov 2002; status: completed.
02
Design
- Study design
- Non-randomizedOpen-label
03
Who it enrols
Patients with histologically confirmed metastatic renal cell carcinoma who have progressed after at least one immunotherapy regimen. Patients must have a compatible family donor for the transplant arm.
04
Endpoints
Primary
Survival rate at 18 months
Objective rate of response
Post-transplant immunological reactions and recuperation
Antitumoral activity of this regimen
Beyond the preview
Go deeper on NCT00056095.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00056095.